CA2286442A1 - Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie - Google Patents

Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie Download PDF

Info

Publication number
CA2286442A1
CA2286442A1 CA002286442A CA2286442A CA2286442A1 CA 2286442 A1 CA2286442 A1 CA 2286442A1 CA 002286442 A CA002286442 A CA 002286442A CA 2286442 A CA2286442 A CA 2286442A CA 2286442 A1 CA2286442 A1 CA 2286442A1
Authority
CA
Canada
Prior art keywords
reperfusion
hearts
ischemia
ischaemia
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002286442A
Other languages
English (en)
Inventor
Jean-Francois Bouchard
Daniel Lamontagne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002286442A priority Critical patent/CA2286442A1/fr
Priority to AU10127/01A priority patent/AU1012701A/en
Priority to PCT/CA2000/001242 priority patent/WO2001028588A1/fr
Publication of CA2286442A1 publication Critical patent/CA2286442A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002286442A 1999-10-15 1999-10-15 Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie Abandoned CA2286442A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002286442A CA2286442A1 (fr) 1999-10-15 1999-10-15 Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie
AU10127/01A AU1012701A (en) 1999-10-15 2000-10-16 Cannabinoids as vasodilators and cardioprotectors against ischemia
PCT/CA2000/001242 WO2001028588A1 (fr) 1999-10-15 2000-10-16 Cannabinoides utilises en tant que vasodilatateurs et cardioprotecteurs contre l'ischemie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002286442A CA2286442A1 (fr) 1999-10-15 1999-10-15 Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie

Publications (1)

Publication Number Publication Date
CA2286442A1 true CA2286442A1 (fr) 2001-04-15

Family

ID=4164389

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002286442A Abandoned CA2286442A1 (fr) 1999-10-15 1999-10-15 Compositions pour augmenter la concentration de cannabinoides comme vasodilatateurs et cardioprotecteurs contre l'ischemie

Country Status (3)

Country Link
AU (1) AU1012701A (fr)
CA (1) CA2286442A1 (fr)
WO (1) WO2001028588A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478338A1 (fr) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Polytherapie destinee a traiter, prevenir ou gerer des troubles proliferatifs et des cancers
DE102004052697A1 (de) * 2004-10-29 2006-05-04 Haehner, Thomas, Dr. Pharmazeutische Zubereitungen zur Behandlung von Folgen des Alkoholmissbrauchs, Hepatitis, Pankreatitis, Alzheimererkrankung, Morbus Parkinson, Diabetes, toxischen Nierenerkrankungen, Reperfusionsschäden, der Arteriosklerose sowie als Antidote gegen Umweltgifte und Medikamentenintoxikation
WO2008040360A2 (fr) * 2006-10-04 2008-04-10 Neurokey A/S Utilisation de médicaments induisant une hypothermie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1999026612A1 (fr) * 1997-11-21 1999-06-03 Smithkline Beecham Corporation Nouveaux modulateurs de recepteurs de cannabinoïdes

Also Published As

Publication number Publication date
WO2001028588A1 (fr) 2001-04-26
AU1012701A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
Bouchard et al. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart
Przyklenk et al. " Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow.
Smith et al. Characterization of Δ9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats
Jordan et al. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence
Griffith et al. Endothelium-derived relaxing factor
Pang et al. Pharmacological augmentation of skin flap viability: a hypothesis to mimic the surgical delay phenomenon or a wishful thought
Hori et al. Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization.
Iino et al. Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion
Wallace et al. Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester
Zheng et al. Superoxide dismutase activity and malondialdehyde level in plasma and morphological evaluation of acute severe hemorrhagic shock in rats
Ke et al. A2 adenosine receptor-mediated cardioprotection against reperfusion injury in rat hearts is associated with autophagy downregulation
Suntres et al. Alleviation of paraquat-induced lung injury by pretreatment with bifunctional liposomes containing α-tocopherol and glutathione
Kruuse et al. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig
Yoshimoto et al. Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A
GB2436255A (en) Organ preconditioning, arrest, protection, preservation and recovery (2)
Nakamura et al. A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium
Atkinson et al. Effect of chronic ANG I-converting enzyme inhibition on aging processes. III. Endothelial function of mesenteric arterial bed of rat
Abran et al. Mechanisms of the biphasic effects of peroxides on the retinal vasculature of newborn and adult pigs
Bertele et al. Antithrombotic therapy in coronary artery disease.
Wang et al. 3′, 4′-Dihydroxyflavonol improves post-ischaemic coronary endothelial function following 7 days reperfusion in sheep
Simpson et al. Myocardial ischemia: the potential therapeutic role of prostacyclin and its analogues
Marzocco et al. Calpain inhibitor I reduces intestinal ischemia-reperfusion injury in the rat
Peacock et al. Amphotericin B therapy: past, present, and future
Sercombe et al. Acetylcholine-induced relaxation of rabbit basilar artery in vitro is rapidly reduced by reactive oxygen species in acute hyperglycemia: Role of NAD (P) H oxidase
Kontos et al. Abnormalities of the cerebral microcirculation after traumatic injury: the relationship of hypertension and prostaglandins

Legal Events

Date Code Title Description
FZDE Discontinued